Markus Kalkum
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Markus Kalkum is a Professor at the Beckman Research Institute, City of Hope, USA. His research areas include the molecular interactions of pathogens, cellular responses in various environments, and the development of new therapeutic strategies against cancer. Recent publications explore topics such as hypertension mechanisms, proteomic profiling in blood collection methods, and the role of phosphorylation in cellular signaling.
Articles (14)
Fig S1. SF3B1 mutant CLL samples had pervasive changes in 3’ splice site. Fig S2. Omics analyses identify widespread post-transcriptional upregulation of splicing factors in CLL. Fig S3. Abundance of spliceosome complexes and RNA-binding proteins are associated with clinical outcomes in CLL. Fig S4. METTL3 is consistently upregulated along with differential m6A modification on transcripts of RNA splicing process in CLL. Fig S5. KO or pharmacological inhibition of METTL3 impacts cell growth. Fig S6. KO or pharmacological inhibition of METTL3 impacts apoptosis, cell cycle, and splicing factor abundance. Fig S7. Splicing factors are either direct or indirect targets of METTL3. Fig S8. Validation of association between m6A and splicing factor abundance using dCasRx-METTL3.
Year:
2025
Table S1 shows CLL sample information; Table S2 shows protein expression detected in CLL and normal B cells using TMT proteomics; Table S3 shows top 150 transcripts with highest m6A density in B cells; Table S4 shows sequences of shRNAs, sgRNAs, and primers used in our study; Table S5 shows cellular pathways enriched in our study.
Year:
2025
Plasmodium vivax is the most widespread malaria species with predominance in Latin America and Southeast Asia. Devising effective controls against P. vivax infections presents unique challenges due to the parasite’s exclusive invasion of reticulocytes, a transient developmental stage of red blood cells. The ephemeral nature and limited availability of reticulocytes complicate efforts to establish continuous in vitro cultures to study the parasite’s biology and receptor-ligand interactions. Here, the potential of the erythroid cell lines JK-1 and BEL-A as alternatives to reticulocytes was confirmed through successful parasite invasion, marking the first report of P. vivax entry to BEL-A cells. Furthermore, LC-MS was used to quantitatively compare the membrane proteomes of these cell lines with those of reticulocytes and mature erythrocytes. This analysis revealed significant similarities between the membrane proteomes of JK-1, BEL-A, and reticulocytes. In addition to the known Plasmodium receptors, transferrin receptor protein 1 (TfR1 or CD71), CD98hc, and basigin (BSG), potential receptor candidates involved in the parasite’s invasion pathway were identified, including prohibitin-2 (PHB2), CAT-1 (SLC7A1), ATB(0) (SLC1A5), CD36, integrin beta-1 (ITGB1), and Metal transporter CNNM3. Proximity labeling using TurboID enabled the identification of specific interactions between PvRBP1a 158-650 and TfR1, BSG, and prohibitin-2 in the erythroid cell lines. Notably, this is the first report of prohibitin-2 as a receptor for P. vivax . These findings advance the understanding of P. vivax receptor-ligand interactions and underscore the potential of JK-1 and BEL-A cell lines as alternative models for the study of parasite biology. Author Summary Plasmodium vivax is a major cause of malaria, particularly in Latin America and Southeast Asia. Unlike other malaria parasites, it infects only immature red blood cells (reticulocytes), which are rare and short-lived, making laboratory studies challenging. No continuous in vitro culture system currently exists for P. vivax , limiting research into its invasion mechanisms. In this study, we evaluated two erythroid cell lines, JK-1 and BEL-A, as potential reticulocyte surrogates. We demonstrate that P. vivax can invade both cell types, including BEL-A cells, which had not previously been tested. Comparative analysis revealed key differences in surface protein expression between these cell lines and reticulocytes, compared to mature red blood cells, identifying seven potential parasite-receptor proteins. We further applied a proximity-based protein tagging approach to identify host-parasite interactions mediated by a specific P. vivax protein ligand, RBP1a. This technique revealed a potential role for prohibitin-2, TfR1, and basigin in mediating P. vivax entry into red blood cells by RBP1a binding. The role of prohibitin-2 as a Plasmodium receptor is a novel Discovery. Our results highlight JK-1 and BEL-A cells as valuable tools for P. vivax research and suggest new avenues for investigating host-pathogen interactions, with implications for malaria treatment and vaccine development.
Year:
2025
RNA splicing dysregulation underlies the onset and progression of cancers. In chronic lymphocytic leukemia (CLL), spliceosome mutations leading to aberrant splicing occur in ∼20% of patients. However, the mechanism for splicing defects in spliceosome-unmutated CLL cases remains elusive. Through an integrative transcriptomic and proteomic analysis, we discover that proteins involved in RNA splicing are posttranscriptionally upregulated in CLL cells, resulting in splicing dysregulation. The abundance of splicing complexes is an independent risk factor for poor prognosis. Moreover, increased splicing factor expression is highly correlated with the abundance of METTL3, an RNA methyltransferase that deposits N 6 -methyladenosine (m 6 A) on mRNA. METTL3 is essential for cell growth in vitro and in vivo and controls splicing factor protein expression in a methyltransferase-dependent manner through m 6 A modification-mediated ribosome recycling and decoding. Our results uncover METTL3-mediated m 6 A modification as a novel regulatory axis in driving splicing dysregulation and contributing to aggressive CLL. Significance: METTL3 controls widespread splicing factor abundance via translational control of m 6 A-modified mRNA, contributes to RNA splicing dysregulation and disease progression in CLL, and serves as a potential therapeutic target in aggressive CLL. See related commentary by Janin and Esteller, p. 176. This article is highlighted in the In This Issue feature, p. 171
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Collaborators (7)
Jianjun Chen
Director
Beckman Research Institute, City of Hope
Jennifer Brown
Worthington and Margaret Collette Professor of Medicine
Dana-Farber Cancer Institute
Jingyi Jessica Li
Professor and Program Head
Fred Hutch Cancer Center
Xinzhou Ge
Assistant professor
Oregon State University
Michihiro Nakamura
Professor
Yamaguchi University Graduate School of Medicine
Steven Rosen
Provost & Chief Scientific Officer
City of Hope
Tanya Siddiqi
Associate Professor
City Of Hope National Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.